Avtal
Avtal
Sidan uppdaterad 2023-06-20
Regionerna samverkar kring att nå avtalsrelationer med läkemedelsföretag för både recept- och rekvisitionsläkemedel. Avtalen kan ofta utgöra en förutsättning för en NT-rådsrekommendation men kan även baseras på andra skäl för regionsamverkan. Det gäller till exempel vissa receptläkemedel där samverkan med TLV och läkemedelsföretag (så kallad trepartsöverläggning) kan leda fram till avtal som samtliga regioner tecknar. Regionernas arbete med avtal stöds och koordineras av de gemensamma funktionerna Marknad och Förhandling.
Sammanställningen nedan omfattar de avtal som tagits fram gemensamt inom ramen för regionernas samverkansmodell för läkemedel och innehåller endast aktuella, giltiga avtal.
Klicka på kolumnrubriken för att sortera
ATC-kod | Substans | Läkemedel | Företag (avtalspart) | Recept/rekvisition | Avtalsstart | Avtalsslut | Förl. option tom. |
|---|---|---|---|---|---|---|---|
A16AB02 | imiglukeras | Cerezyme | Sanofi AB | rekvisition | 2023-04-01 | 2025-03-31 | 2027-03-31 |
A16AB21 | atidarsagen-autotemcel | Libmeldy | Orchad Therapeutics (Netherlands) BV | rekvisition | 2023-02-01 | 2025-01-31 | 2027-01-31 |
A16AX07 | sapropterin | Kuvan | BioMarin International | recept | 2020-11-01 | 2023-10-31 | . |
A16AX15 | telotristatetyl | Xermelo | Serb S.A.S. | recept | 2021-06-01 | 2024-05-31 | . |
A16AX16 | givosiran | Givlaari | Alnylam Sweden AB | recept | 2022-07-01 | 2024-06-30 | 2025-06-30 |
B01AX07 | kaplacizumab | Cablivi | Sanofi AB | rekvisition | 2021-10-01 | 2023-09-30 | 2025-09-30 |
B02BD02 | koagulations-faktor VIII | Advate | Takeda Pharma AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD02 | koagulations-faktor VIII | Adynovi | Takeda Pharma AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD02 | koagulations-faktor VIII | Afstyla | CSL Behring AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD02 | koagulations-faktor VIII | Elocta | Swedish Orphan Biovitrum | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD02 | koagulations-faktor VIII | Esperoct | Novo Nordisk AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD02 | koagulations-faktor VIII | Jivi | Bayer AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD02 | koagulations-faktor VIII | Kovaltry | Bayer AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD02 | koagulations-faktor VIII | NovoEight | Novo Nordisk AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD02 | koagulations-faktor VIII | Nuwiq | Octapharma Nordic AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD02 | koagulations-faktor VIII | Octanate LV | Octapharma Nordic AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD02 | koagulations-faktor VIII | Refacto AF | Pfizer AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B02BD04 | koagulations-faktor IX | Alprolix | Swedish Orphan Biovitrum | recept | 2020-10-01 | 2023-09-30 | . |
B02BD04 | koagulations-faktor IX | BeneFIX | Pfizer AB | recept | 2020-10-01 | 2023-09-30 | . |
B02BD04 | koagulations-faktor IX | Immunine | Takeda Pharma AB | recept | 2020-10-01 | 2023-09-30 | . |
B02BD04 | koagulations-faktor IX | Nanofix | Octapharma Nordic AB | recept | 2020-10-01 | 2023-09-30 | . |
B02BD04 | koagulations-faktor IX | Refixia | Novo Nordisk AB | recept | 2020-10-01 | 2023-09-30 | . |
B02BX06 | emicizumab | Hemlibra | Roche AB | recept | 2023-06-01 | 2025-05-31 | 2026-05-31 |
B06AC05 | lanadelumab | Takhzyro | Takeda Pharma AB | recept | 2022-01-01 | 2023-12-31 | 2024-12-31 |
B06AV06 | berotralstat | Orladeyo | BioCryst Ireland | recept | 2022-01-01 | 2023-12-31 | 2024-12-31 |
B06AX01 | krizanlizumab | Adakveo | Novartis Sverige AB | rekvisition | 2022-04-01 | 2024-03-31 | 2026-03-31 |
C10AX13 | evolocumab | Repatha | Amgen AB | recept | 2022-01-01 | 2023-12-31 | 2024-12-31 |
C10AX14 | alirocumab | Praluent | Sanofi AB | recept | 2022-01-01 | 2023-12-31 | 2024-12-31 |
C10AX16 | inklisiran | Leqvio | Novartis Sverige AB | rekvisition | 2022-10-01 | 2024-09-30 | 2026-09-30 |
D11AH05 | dupilumab | Dupixent | Sanofi AB | recept | 2023-01-01 | 2024-12-31 | 2025-12-31 |
D11AH08 | abrocitinib | Cibinqo | Pfizer AB | recept | 2022-10-01 | 2023-09-30 | . |
J05AP08 | sofosbuvir | Sovaldi | Gilead Sciences Sweden AB | recept | 2021-01-01 | 2023-12-31 | . |
J05AP51 | ledipasvir + sofosbuvir | Harvoni | Gilead Sciences Sweden AB | recept | 2021-01-01 | 2023-12-31 | . |
J05AP54 | elbasvir + grazoprevir | Zepatier | MSD | recept | 2021-01-01 | 2023-12-31 | . |
J05AP55 | sofosbuvir + velpatasvir | Epclusa | Gilead Sciences Sweden AB | recept | 2021-01-01 | 2023-12-31 | . |
J05AP56 | sofosbuvir + velpatasvir + voxilaprevir | Vosevi | Gilead Sciences Sweden AB | recept | 2021-01-01 | 2023-12-31 | . |
J05AX28 | bulevirtid | Hepcludex | Gilead Sciences Sweden AB | recept | 2022-11-01 | 2024-10-31 | 2025-10-31 |
L01EB04 | osimertinib | Tagrisso | AstraZeneca | recept | 2020-10-01 | 2023-09-30 | . |
L01EE01 | trametinib | Mekinist | Novartis Sverige AB | recept | 2023-01-01 | 2024-12-31 | 2025-12-31 |
L01EE03 | binimetinib | Mektovi | Pierre Fabre | recept | 2023-01-01 | 2024-12-31 | 2025-12-31 |
L01EH03 | tukatinib | Tukysa | Seagen B.V. | recept | 2022-05-01 | 2024-04-30 | 2025-04-30 |
L01EL01 | ibrutinib | Imbruvica | Janssen Cilag AB | recept | 2022-10-01 | 2024-09-30 | 2025-09-30 |
L01EL02 | akalabrutinib | Calquence | AstraZeneca AB | recept | 2023-06-01 | 2024-09-30 | 2025-09-30 |
L01EL03 | zanubrutinib | Brukinsa | BeiGene Sweden AB | recept | 2023-06-01 | 2024-09-30 | 2025-09-30 |
L01EX07 | cabozantinib | Cabometyx | Ipsen | recept | 2021-04-01 | 2024-03-31 | . |
L01EX13 | gilteritinib | Xospata | Astellas Pharma AB | recept | 2021-03-01 | 2024-02-29 | . |
L01EX21 | tepotinib | Tepmetko | Merck Sharp & Dohme (Sweden) AB | recept | 2023-05-01 | 2025-04-30 | 2026-04-30 |
L01FC01 | daratumumab | Darzalex | Janssen Cilag AB | rekvisition | 2020-07-01 | 2024-06-30 | . |
L01FD02 | pertuzumab | Perjeta | Roche AB | rekvisition | 2023-01-01 | 2024-12-31 | 2026-12-31 |
L01FD03 | trastuzumab- emtansin | Kadcyla | Roche AB | rekvisition | 2020-01-01 | 2023-12-31 | . |
L01FD04 | trastuzumab deruxtekan | Enhertu | Daiichi Sankyo Nordics ApS | rekvisition | 2021-12-01 | 2023-11-30 | 2025-11-30 |
L01FF01 | nivolumab | Opdivo | Bristol-Myers Squibb AB | rekvisition | 2021-01-01 | 2023-12-31 | 2024-12-31 |
L01FF02 | pembrolizumab | Keytruda | Merck Sharp & Dohme (Sweden) AB | rekvisition | 2021-01-01 | 2023-12-31 | 2024-12-31 |
L01FF03 | durvalumab | Imfinzi | AstraZeneca | rekvisition | 2021-01-01 | 2023-12-31 | 2024-12-31 |
L01FF04 | avelumab | Bavencio | Merck | rekvisition | 2021-01-01 | 2023-12-31 | 2024-12-31 |
L01FF05 | atezolizumab | Tecentriq | Roche AB | rekvisition | 2021-01-01 | 2023-12-31 | 2024-12-31 |
L01FF06 | cemiplimab | Libtayo | Sanofi AB | rekvisition | 2021-01-01 | 2023-12-31 | 2024-12-31 |
L01FF07 | dostarlimab | Jemperli | GlaxoSmithKline | rekvisition | 2022-09-01 | 2023-12-31 | 2024-12-31 |
L01FG02 | ramucirumab | Cyramza | Lilly | rekvisition | 2020-12-01 | 2023-11-30 | 2024-11-30 |
L01FX04 | ipilimumab | Yervoy | Bristol-Myers Squibb AB | rekvisition | 2023-01-01 | 2024-12-31 | 2026-12-31 |
L01FX13 | enfortumab vedotin | Padcev | Astellas Pharma AB | rekvisition | 2023-01-01 | 2024-12-31 | 2026-12-31 |
L01FX14 | polatuzumab vedotin | Polivy | Roche AB | rekvisition | 2020-09-01 | 2023-08-31 | 2024-08-31 |
L01FX17 | sacituzumab-govitekan | Trodelvy | Gilead Sciences Sweden AB | rekvisition | 2022-07-01 | 2024-06-30 | 2026-06-30 |
L01XG02 | karfilzomib | Kyprolis | Amgen AB | rekvisition | 2021-04-01 | 2024-03-31 | 2025-03-31 |
L01XG03 | ixazomib | Ninlaro | Takeda Pharma | recept | 2021-06-01 | 2024-05-31 | . |
L01XK02 | niraparib | Zejula | GlaxoSmithKline | recept | 2022-12-01 | 2024-11-30 | 2025-11-30 |
L01XK04 | talazoparib | Talzenna | Pfizer AB | recept | 2021-06-01 | 2024-05-31 | . |
L01XL03 | axikabtagen-ciloleucel | Yescarta | Gilead Sciences Sweden AB | rekvisition | 2021-06-01 | 2024-05-31 | . |
L01XL04 | tisagenlekleucel | Kymriah | Novartis Sverige AB | rekvisition | 2021-06-01 | 2024-05-31 | . |
L01XL06 | brexukabtagen-autoleucel | Tecartus | Gilead Sciences Sweden AB | rekvisition | 2022-12-01 | 2024-05-31 | . |
L01XX52 | venetoklax | Venclyxto | AbbVie AB | recept | 2021-05-01 | 2024-04-30 | . |
L01XY02 | trastuzumab/ pertuzumab | Phesgo | Roche AB | rekvisition | 2021-03-01 | 2024-02-28 | 2025-02-28 |
L02BB04 | enzalutamid | Xtandi | Astellas Pharma AB | recept | 2022-10-01 | 2024-04-30 | . |
L02BB05 | apalutamid | Erleada | Janssen-Cilag AB | recept | 2021-05-01 | 2024-04-30 | . |
L02BB06 | darolutamid | Nubeqa | Bayer AB | recept | 2021-05-01 | 2024-04-30 | . |
L04AA29 | tofacitinib | Xeljanz | Pfizer AB | recept | 2020-10-01 | 2023-09-30 | . |
L04AA37 | baricitinib | Olumiant | Lilly | recept | 2020-10-01 | 2023-09-30 | . |
L04AA41 | imlifidas | Idefirix | Hansa Biopharma AB | rekvisition | 2021-07-01 | 2024-06-30 | 2025-06-30 |
L04AA43 | ravulizumab | Ultomiris | Alexion Pharma Nordics AB | rekvisition | 2021-03-01 | 2023-09-30 | 2025-02-28 |
L04AA44 | upadacitinib | Rinvoq | Abbvie AB | recept | 2020-10-01 | 2023-09-30 | |
L04AA45 | filgotinib | Jyseleca | Galapagos NV | recept | 2021-04-01 | 2023-09-30 | . |
M05BX05 | burosumab | Crysvita | Kyowa Kirin | rekvisition | 2023-06-01 | 2023-11-30 | . |
M09AX03 | ataluren | Translarna | PTC Therapeutics International Ltd | rekvisition | 2022-07-01 | 2023-12-31 | . |
M09AX07 | nusinersen | Spinraza | Biogen Sweden AB | rekvisition | 2022-12-01 | 2023-11-30 | 2024-05-31 |
M09AX09 | onasemnogen abeparvovek | Zolgensma | Novartis Gene Therapies EU Limited | rekvisition | 2022-02-01 | 2024-01-31 | 2026-01-31 |
M09AX10 | risdiplam | Evrysdi | Roche AB | rekvisition | 2021-12-01 | 2023-11-30 | 2025-11-30 |
N07XX08 | tafamidis | Vyndaqel 61 mg | Pfizer AB | recept | 2021-09-01 | 2023-08-31 | 2024-08-31 |
N07XX12 | patisiran | Onpattro | Alnylam Sweden | rekvisition | 2019-11-01 | 2023-10-31 | . |
N07XX15 | inotersen | Tegsedi | Akcea Therapeutics Ireland Ltd | rekvisition | 2019-11-01 | 2023-10-31 | . |
R07AX02 | ivakaftor | Kalydeco | Vertex Pharmaceuticals Europé | recept | 2022-12-01 | 2026-12-31 | 2028-12-31 |
R07AX30 | lumakaftor/ivakaftor | Orkambi | Vertex Pharmaceuticals Europé | recept | 2022-12-01 | 2026-12-31 | 2028-12-31 |
R07AX31 | tezakaftor/ivakaftor | Symkevi | Vertex Pharmaceuticals Europé | recept | 2022-12-01 | 2026-12-31 | 2028-12-31 |
R07AX32 | elaxakaftor/tezakaftor/ivakaftor | Kaftrio | Vertex Pharmaceuticals Europé | recept | 2022-12-01 | 2026-12-31 | 2028-12-31 |
S01XA27 | voretigene neparvovek | Luxturna | Novartis Sverige AB | rekvisition | 2022-05-01 | 2024-04-30 | 2026-04-30 |
V10XX04 | Iutetium(Lu-177) oxodotreotid | Lutathera | SAM Nordic | rekvisition | 2022-09-01 | 2024-08-31 | 2026-08-31 |